Anticancer potential of cryptotanshinone on breast cancer treatment; A narrative review

被引:15
作者
Dalil, Davood [1 ]
Iranzadeh, Saeid [1 ]
Kohansal, Soroush [1 ]
机构
[1] Shahed Univ, Student Res Comm, Fac Med, Tehran, Iran
关键词
salvia miltiorrhiza; cryptotanshinon; tanshinone C; breast cancer; molecular mechanism; drug combination; estrogen receptor; ESTROGEN-RECEPTOR; INHIBITS PROLIFERATION; MOLECULAR-MECHANISMS; BETA-CATENIN; RISK-FACTORS; RESISTANCE; APOPTOSIS; CELLS; INDUCTION; CARCINOMA;
D O I
10.3389/fphar.2022.979634
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer has recently been known as the first lethal malignancy in women worldwide. Despite the existing treatments that have improved the patients' prognosis, some types of breast cancer are serious challenges to treat. Therefore, efforts are underway to provide more efficient therapy. Cryptotanshinone (CPT) is a liposoluble diterpenoid derivation of a traditional Chinese herbal medicine called Salvia miltiorrhiza Bunge. It has been considered in the past decades due to its vast therapeutic properties, including anti-tumor, anti-inflammatory, and anti-fibrosis. Recently, studies have found that CPT showed a significant anti-breast cancer effect in vivo and in vitro through different physiological and immunological mechanisms. This study summarized the latest research findings on the antitumor effect of CPT in breast cancer. Further, the main molecular mechanisms based on breast cancer types and combination with other drugs were reviewed to provide essential evidence for future longitudinal research and its clinical application in breast cancer treatment.
引用
收藏
页数:9
相关论文
共 68 条
  • [1] Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health
    Abderrahman, Balkees
    Jordan, V. Craig
    [J]. ENDOCRINOLOGY, 2018, 159 (08) : 2980 - 2990
  • [2] FoxO Transcription Factors Support Oxidative Stress Resistance in Human Chondrocytes
    Akasaki, Yukio
    Alvarez-Garcia, Oscar
    Saito, Masahiko
    Carames, Beatriz
    Iwamoto, Yukihide
    Lotz, Martin K.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 (12) : 3349 - 3358
  • [3] Risk Factors of Breast Cancer: A Systematic Review and Meta-Analysis
    Anothaisintawee, Thunyarat
    Wiratkapun, Cholatip
    Lerdsitthichai, Panuwat
    Kasamesup, Vijj
    Wongwaisayawan, Sansanee
    Srinakarin, Jiraporn
    Hirunpat, Siriporn
    Woodtichartpreecha, Piyanoot
    Boonlikit, Sarawan
    Teerawattananon, Yot
    Thakkinstian, Ammarin
    [J]. ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH, 2013, 25 (05) : 368 - 387
  • [4] The G Protein-Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor-Positive Breast Cancer Cells
    Ariazi, Eric A.
    Brailoiu, Eugen
    Yerrum, Smitha
    Shupp, Heather A.
    Slifker, Michael J.
    Cunliffe, Heather E.
    Black, Michael A.
    Donato, Anne L.
    Arterburn, Jeffrey B.
    Oprea, Tudor I.
    Prossnitz, Eric R.
    Dun, Nae J.
    Jordan, V. Craig
    [J]. CANCER RESEARCH, 2010, 70 (03) : 1184 - 1194
  • [5] The pharmacology of leishmaniasis
    Balaña-Fouce, R
    Reguera, RM
    Cubría, JC
    Ordóñez, D
    [J]. GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1998, 30 (04): : 435 - 443
  • [6] Lead Optimization of 2-Cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides for Targeting the HER-2 Overexpressed Breast Cancer Cell Line SKBr-3
    Bhat, Mashooq A.
    Al-Dhfyan, Abdullah
    Naglah, Ahmed M.
    Khan, Azmat Ali
    Al-Omar, Mohamed A.
    [J]. MOLECULES, 2015, 20 (10): : 18246 - 18263
  • [7] Environmental pollutants, diet, physical activity, body size, and breast cancer - Where do we stand in research to identify opportunities for prevention?
    Brody, Julia Green
    Rudel, Ruthann A.
    Michels, Karin B.
    Moysich, Kirsten B.
    Bernstein, Leslie
    Attfield, Kathleen R.
    Gray, Sharon
    [J]. CANCER, 2007, 109 (12) : 2627 - 2634
  • [8] A 2009 Update on the Treatment of Patients with Hormone Receptor-Positive Breast Cancer
    Cleator, Susan J.
    Ahamed, Eliyaz
    Coombes, R. Charles
    Palmieri, Carlo
    [J]. CLINICAL BREAST CANCER, 2009, 9 : S6 - S17
  • [9] Nature: a vital source of leads for anticancer drug development
    Cragg, G. M.
    Newman, D. J.
    [J]. PHYTOCHEMISTRY REVIEWS, 2009, 8 (02) : 313 - 331
  • [10] Deep G, 2013, CURR CANCER DRUG TAR, V13, P486